دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence
Kamlesh Khunti PhD, Vanita R. Aroda MD, Deepak L. Bhatt MD, Biykem Bozkurt MD, John B. Buse MD, Hiddo L. Heerspink PhD, Silvio E. Inzucchi MD, Carolyn S. P. Lam PhD, Nikolaus Marx MD, John J. V. McMurray MD, Scott D. Solomon MD, Mikhail N. Kosiborod MD,Â
doi : 10.1111/dom.14805
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are now seen as an integral part of therapy in type 2 diabetes to control not only blood glucose but to improve cardiovascular and kidney outcomes. Diabetic ketoacidosis (DKA) is an uncommon but serious complication of type 2 diabetes, which has a high case fatality rate.
Glucagon-like peptide-1 effect on β-cell function varies according to diabetes remission status after Roux-en-Y gastric bypass
Ankit Shah MD, Malini Prasad MS, Victoria Mark MS, Jens Juul Holst MD, Blandine Laferrère MD,Â
doi : 10.1111/dom.14793
The contribution of endogenous glucagon-like peptide (GLP)-1 to β-cell function after Roux-en-Y gastric bypass surgery (RYGB) is well established in normoglycaemic individuals, but not in those with postoperative hyperglycaemia. We, therefore, studied the effect of GLP-1 on β-cell function in individuals with varying degrees of type 2 diabetes mellitus (T2D) control after RYGB.
In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist
Ben Jones PhD, Vinod Burade PhD, Elina Akalestou PhD, Yusman Manchanda MSc, Zenouska Ramchunder MSc, Gaëlle Carrat PhD, Marie-Sophie Nguyen-Tu PhD, Piero Marchetti MD, Lorenzo Piemonti MD, Isabelle Leclerc MD, PhD, Rajamannar Thennati PhD, Tina Vilsboll MD, DMSc, Bernard Thorens PhD, Alejandra Tomas PhD, Guy A. Rutter PhD,Â
doi : 10.1111/dom.14794
To describe the in vitro characteristics and antidiabetic in vivo efficacy of the novel glucagon-like peptide-1 receptor agonist (GLP-1RA) GL0034.
Real world hypoglycaemia related to glucose variability and Flash glucose scan frequency assessed from global FreeStyle Libre data
Jean-Pierre Riveline MD, Anne Wojtusciszyn MD, Bruno Guerci MD, Clara Alves MD, Kalvin Kao MS, Yongjin Xu PhD, Timothy C. Dunn PhD,Â
doi : 10.1111/dom.14795
Flash glucose monitoring provides a range of glucose metrics. In the current study, we aim to identify those that indicate that glycaemic targets can be consistently met and contrast the total (t-CV) and within-day coefficient of variation (wd-CV) to guide the assessment of glucose variability and hypoglycaemia exposure.
Hospital costs associated with adverse events in people with diabetes in the UK
Mi Jun Keng MSc, Jose Leal DPhil, Louise Bowman MD, Jane Armitage MBBS, Borislava Mihaylova DPhil, on behalf of the ASCEND Study Collaborative Group ,Â
doi : 10.1111/dom.14796
To estimate the annual hospital costs associated with a range of adverse events for people with diabetes in the UK.
Prediabetes diagnosis is associated with the progression of coronary artery calcification: The Kangbuk Samsung Health Study
In Young Choi MD, Yoosoo Chang MD, Yoosun Cho MD, Jeonggyu Kang MD, Hyun-Suk Jung MD, Sarah H. Wild PhD, Christopher D. Byrne MBBCh, Seungho Ryu MD,Â
doi : 10.1111/dom.14797
To investigate the associations between prediabetes defined by different diagnostic criteria and coronary artery calcification (CAC) and its progression over time.
Prognostic value of 24-hour ambulatory blood pressure patterns in diabetes: A 21-year longitudinal study
Martina Chiriacò MD, Luca Sacchetta MD, Giovanna Forotti MD, Simone Leonetti MSc, Lorenzo Nesti MD, Stefano Taddei MD, Andrea Natali MD, Anna Solini MD, Domenico Tricò MD,Â
doi : 10.1111/dom.14798
To establish the long-term prognostic value of abnormal circadian blood pressure (BP) patterns in diabetes.
Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease
Iskandar Idris MD, Ruiqi Zhang PhD, Jil B. Mamza PhD, Mike Ford BSc, Tamsin Morris BSc, Amitava Banerjee MD, Kamlesh Khunti MD,Â
doi : 10.1111/dom.14799
To confirm the reno-protective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with dipeptidyl peptidase-4 (DPP-4) inhibitors on the onset and progression of chronic kidney disease (CKD) in routine clinical practice.
Bromocriptine quick-release as adjunct therapy in youth and adults with type 1 diabetes: A randomized, placebo-controlled crossover study
Shoshana S. Tell MD, Michal Schafer PhD, Timothy Vigers BA, Amy D. Baumgartner MSc, Ellen Lyon MS, Susan Gross MS, Sarit Polsky MD, Janet K. Snell-Bergeon PhD, Irene E. Schauer MD, Kristen J. Nadeau MD,Â
doi : 10.1111/dom.14800
To evaluate the potential for glycaemic, renal and vascular benefits of bromocriptine quick release (BCQR) in adolescents and adults with type 1 diabetes.
Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis
Shuo Yang MS, Lu Zhao MS, Yaochuan Mi MS, Wei He MS,Â
doi : 10.1111/dom.14801
To compare the efficacy of sodium-glucose cotransporter-2 (SGLT2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists (MRAs), selective aldosterone antagonists and nonselective aldosterone antagonists, on top of renin-angiotensin-aldosterone system (RAAS) blockade, in reducing kidney-specific composite events, cardiovascular outcomes, and other events of special interest in participants with type 2 diabetes (T2D) and chronic kidney disease (CKD).
The association of long-acting insulin analogue use versus neutral protamine Hagedorn insulin use and the risk of major adverse cardiovascular events among individuals with type 2 diabetes: A population-based cohort study
Vanessa C. Brunetti PhD, Oriana Hoi Yun Yu MD, Robert W. Platt PhD, Kristian B. Filion PhD,Â
doi : 10.1111/dom.14802
To compare the risk of cardiovascular outcomes associated with long-acting insulin analogues versus neutral protamine Hagedorn (NPH) insulin among patients with type 2 diabetes.
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial
Xiaoyong Yuan MD, Xiaohui Guo MD, Junqing Zhang MD, Xiaolin Dong MD, Yibing Lu MD, Wuyan Pang MD, Shenghong Gu MCM, Elisabeth Niemoeller MD, Lin Ping MD, Gaowei Nian MSc, Elisabeth Souhami MD, on behalf of the LixiLan-L-CN investigators ,Â
doi : 10.1111/dom.14803
To evaluate the efficacy and safety of iGlarLixi compared with iGlar in Chinese adults with type 2 diabetes advancing therapy from basal insulin ± oral antihyperglycaemic drugs.
The effect of curcumin on hepatic fat content in individuals with obesity
Pernille H. Hellmann MD, Jonatan I. Bagger MD, Katrine R. Carlander Medical Student, Julie Forman PhD, Elizaveta Chabanova PhD, Jens S. Svenningsen Medical Student, Jens J. Holst MD, Matthew P. Gillum PhD, Tina Vilsbøll MD, Filip K. Knop MD,Â
doi : 10.1111/dom.14804
In a double-blind, parallel-group trial, 37 obese, non-diabetic individuals were randomized to placebo or curcumin treatment for 6 weeks. Curcumin was dosed as lecithin-formulated tablet; 200 mg twice daily.
Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM-CURE risk score
Yilu Lin PhD, Hui Shao PhD, Lizheng Shi PhD, Amanda H. Anderson PhD, Vivian Fonseca MD,Â
doi : 10.1111/dom.14806
Early identification and prediction of incident heart failure (HF) is important because of severe morbidity and mortality. This study aimed to predict onset of HF among patients with diabetes.
Predictors of time in target glucose range in real-world users of the MiniMed 780G system
Javier Castañeda, Chantal Mathieu, Henk-Jan Aanstoot, Arcelia Arrieta, Julien Da Silva, John Shin, Ohad Cohen,Â
doi : 10.1111/dom.14807
Automated insulin delivery systems have improved glycaemic control in people with type 1 diabetes mellitus. The analysis investigated predictors of improved sensor glucose time-in-range (TIR; 70-180 mg/dl) based on real-world use of the MiniMed 780G advanced hybrid closed-loop (AHCL) system.
The absolute risk of incident type 2 diabetes following exposure to systemic corticosteroids in selected steroid-related and phenotypic groups
Philip Ambery FRCP, Samuel Adamsson Eryd PhD, Sara Jenkins-Jones MSc, Ben Heywood BSc, Ellen Berni MSc, Mary N. Brown Pharm D, Carol Astbury PhD, Phillip Hunt Sc.D, Craig J. Currie PhD,Â
doi : 10.1111/dom.14808
Exposure to corticosteroids is known to increase the risk of developing type 2 diabetes. We estimated the risk of incident type 2 diabetes in selected patient groups exposed to systemic corticosteroids.
Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial
Jianping Xu MD, Hongwei Ling MD, Jianlin Geng MD, Investigators , Yanli Huang BSc, Ying Xie MD, Huiping Zheng MSc, Huikun Niu MD, Tianhao Zhang MD, Jing Yuan MD, Xinhua Xiao MD,Â
doi : 10.1111/dom.14810
To evaluate the efficacy and safety of DBPR108 (prusogliptin), a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, as an add-on therapy in patients with type 2 diabetes (T2D) that is inadequately controlled with metformin.
The glucose tolerance test in mice: Sex, drugs and protocol
Matilda R. Kennard PhD, Manasi Nandi PhD, Sarah Chapple PhD, Aileen J. King PhD,Â
doi : 10.1111/dom.14811
To establish the impact of sex, dosing route, fasting duration and acute habituation stress on glucose tolerance test (GTT) measurements used in the preclinical evaluation of potential glucose-modulating therapeutics.
Disease heterogeneity of adult diabetes based on routine clinical variables at diagnosis: Results from the German/Austrian Diabetes Follow-up Registry
Julia M. Grimsmann PhD, Sascha R. Tittel MS, Peter Bramlage MD, Benjamin Mayer PhD, Andreas Fritsche MD, Jochen Seufert MD, Markus Laimer MD, Stefan Zimny MD, Sebastian M. Meyhoefer MD, Michael Hummel MD, Reinhard W. Holl MD,Â
doi : 10.1111/dom.14812
We applied hierarchical clustering using Ward's method to 56 869 adults documented in the prospective Diabetes Follow-up Registry (DPV). Clustering variables included age, sex, body mass index (BMI), HbA1c, diabetic ketoacidosis (DKA), components of the metabolic syndrome (hypertension/dyslipidaemia/hyperuricaemia) and beta-cell antibody status.
The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis
Julia Moellmann PhD, Pascal A. Mann MD, Ben A. Kappel MD, Florian Kahles MD, Barbara M. Klinkhammer PhD, Peter Boor MD, Rafael Kramann MD, Bart Ghesquiere PhD, Corinna Lebherz MD, Nikolaus Marx MD, Michael Lehrke MD,Â
doi : 10.1111/dom.14814
To investigate cardiac signalling pathways connecting substrate utilization with left ventricular remodelling in a murine pressure overload model.
Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial
Søren Snitker MD, Christina Egebjerg PhD, Marie Frederiksen MSc, Thomas Sparre MD,Â
doi : 10.1111/dom.14809
Response to Boonpor et al: Types of diet, obesity, and incident type 2 diabetes: Findings from the UK Biobank prospective cohort study
Conor James MacDonald PhD, Pauline Frenoy MSc, Marie-Christine Boutron-Ruault PhD,Â
doi : 10.1111/dom.14813
